company background image
NBIX

Neurocrine Biosciences NasdaqGS:NBIX Stock Report

Last Price

US$108.38

Market Cap

US$10.4b

7D

-2.7%

1Y

41.2%

Updated

27 Jan, 2023

Data

Company Financials +

Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Mkt Cap: US$10.4b

NBIX Stock Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.

NBIX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance1/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Neurocrine Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neurocrine Biosciences
Historical stock prices
Current Share PriceUS$108.38
52 Week HighUS$129.29
52 Week LowUS$73.13
Beta0.52
1 Month Change-8.68%
3 Month Change-6.22%
1 Year Change41.25%
3 Year Change8.29%
5 Year Change30.06%
Change since IPO767.04%

Recent News & Updates

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Dec 08
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Recent updates

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Dec 08
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Jul 26
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?

Apr 11
Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?

Here's Why I Think Neurocrine Biosciences (NASDAQ:NBIX) Might Deserve Your Attention Today

Jan 04
Here's Why I Think Neurocrine Biosciences (NASDAQ:NBIX) Might Deserve Your Attention Today

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Stay On Top Of Its Debt

Dec 09
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Stay On Top Of Its Debt

I Ran A Stock Scan For Earnings Growth And Neurocrine Biosciences (NASDAQ:NBIX) Passed With Ease

Oct 02
I Ran A Stock Scan For Earnings Growth And Neurocrine Biosciences (NASDAQ:NBIX) Passed With Ease

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Aug 27
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Earnings Not Telling The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Jun 08
Earnings Not Telling The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO For Now

May 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO For Now

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

May 04
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Introducing Neurocrine Biosciences (NASDAQ:NBIX), The Stock That Zoomed 210% In The Last Five Years

Mar 01
Introducing Neurocrine Biosciences (NASDAQ:NBIX), The Stock That Zoomed 210% In The Last Five Years

We Think Neurocrine Biosciences' (NASDAQ:NBIX) Statutory Profit Might Understate Its Earnings Potential

Feb 02
We Think Neurocrine Biosciences' (NASDAQ:NBIX) Statutory Profit Might Understate Its Earnings Potential

Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today?

Jan 12
Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today?

Shareholder Returns

NBIXUS BiotechsUS Market
7D-2.7%0.7%2.3%
1Y41.2%7.1%-9.7%

Return vs Industry: NBIX exceeded the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: NBIX exceeded the US Market which returned -9.7% over the past year.

Price Volatility

Is NBIX's price volatile compared to industry and market?
NBIX volatility
NBIX Average Weekly Movement5.2%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: NBIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: NBIX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19921,150Kevin Gormanhttps://www.neurocrine.com

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.

Neurocrine Biosciences, Inc. Fundamentals Summary

How do Neurocrine Biosciences's earnings and revenue compare to its market cap?
NBIX fundamental statistics
Market CapUS$10.42b
Earnings (TTM)US$58.20m
Revenue (TTM)US$1.39b

179.0x

P/E Ratio

7.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NBIX income statement (TTM)
RevenueUS$1.39b
Cost of RevenueUS$452.80m
Gross ProfitUS$935.90m
Other ExpensesUS$877.70m
EarningsUS$58.20m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 06, 2023

Earnings per share (EPS)0.61
Gross Margin67.39%
Net Profit Margin4.19%
Debt/Equity Ratio11.0%

How did NBIX perform over the long term?

See historical performance and comparison